Question 1

How much does a Sequencing Assessment cost?

Accepted Answer

A fixed fee, agreed before kick-off. The figure varies by asset complexity and the number of candidate markets in scope, but it sits in a range a biotech or medtech in the run-up to launch can comfortably absorb against the cost of one wasted quarter of launch planning. We'll quote once we understand your asset and needs. We won't waste your time with a generic price list that wouldn't apply to your situation.

Question 2

How long does the Assessment take?

Accepted Answer

A few weeks from kick-off to board-ready output. Most Assessments run in the four-to-six week range. Your team's time commitment is roughly two working sessions per week — a kick-off, a data review, calibration sessions on market scoring and sequence modeling, and a final readout. We're built to fit around your operating rhythm, not to consume it.

Question 3

What if we already have a launch plan?

Accepted Answer

Good — bring it. The Assessment is faster and sharper when there's an existing thesis to pressure-test. We've seen launch plans that needed a complete reordering and we've seen ones that needed a single critical adjustment. Either way, the artifacts you walk away with are defensible by your team, not just by ours.

Question 4

Do you actually execute the launch, or just advise on it?

Accepted Answer

We lead the regulatory, market access, pricing, and evidence work that gets each market launch-ready. We design the post-launch strategy that drives uptake. We don't run your sales force, build your brand, or execute commercial promotion — that stays with your team. The boundary is deliberate. Commercial execution belongs with the people who own the long-term commercial relationship; our job is to make sure they're set up to win it.

Question 5

We're considering several consulting firms. Why Cenvia?

Accepted Answer

Three things distinguish us. First, we treat sequencing as the strategy, not as the planning step before the strategy. Second, the principals you meet on the discovery call are the principals who lead the work — there's no bait-and-switch onto associates. Third, we operate at depth in regions most boutique firms skip, particularly MENA and GCC. If your launch genuinely doesn't need any of those things, another firm may be a better fit, and we'll say so.

Question 6

Can we do execution without doing the Sequencing Assessment first?

Accepted Answer

Almost always, no — and for a practical reason. Execution choices are downstream of sequencing choices, and starting in the wrong market is the most expensive mistake in launch planning. The Sequencing Assessment exists because we'd rather have that conversation first, on a fixed fee, than discover it mid-engagement.

The exception: if you've already done a rigorous sequencing exercise — internally or with another partner — and you can defend the thesis to your board, we'll review it. If the logic holds, we'll engage on execution directly. If it doesn't, we'll tell you, and we'll suggest where the Assessment would tighten it.
Most clients find the Assessment is short when sequencing is sound, and worth doing when it isn't. Either way, the conversation starts with what you've already decided.

Question 7

What kinds of assets and companies do you work with best?

Accepted Answer

Biotechs with pivotal data on the horizon. Medtechs with regulatory, reimbursement, or evidence complexity. Innovative assets where the comparator and HTA strategy are unsettled. Teams whose plans already extend beyond a single home market.

Question 8

Where are you based, and where do you work?

Accepted Answer

We're a London-headquartered firm. We work across the United States, Europe, MENA and GCC, and Asia. Engagements are typically run as a mix of remote and on-site work, with principal presence in the markets that matter most for your sequence. We don't require travel from your team; we come to you.

Question 9

Who actually does the work?

Accepted Answer

Principals — senior operators who have led launches end-to-end inside biopharma and medtech companies — own outcomes and stay accountable across the engagement. Modality consultants from a vetted bench are activated underneath the principal when the work demands their depth: cell and gene therapy, rare disease, oncology, AI/SaMD, surgical robotics, diagnostics and more. Activated when needed, retired when not.

Question 10

What happens after the Sequencing Assessment?

Accepted Answer

Most Assessments hand off into execution — Launch Studio for the first markets, Market Accelerator for the next, Adoption Strategy once approvals are in hand. But not every Assessment leads to a Cenvia engagement, and we don't structure it as if it should. Some teams take the sequence and execute internally. Some take it elsewhere. The artifacts are yours either way.

Question 11

How do we get started?

Accepted Answer

A discovery call with one of the principals — thirty minutes, no commitment. We'll ask about your asset, your timeline, the markets you're considering, and what your board is expecting. By the end of the call, we'll both know whether a Sequencing Assessment makes sense. Use the form above, or email info@cenvia.eu directly.

Talk to a princıpal.

Before you book, you might be wondering: